Navigation Links
Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire

CHARLESTON, S.C., Feb. 12 /PRNewswire/ -- Charleston Laboratories, Inc, an emerging specialty pharmaceutical company dedicated to reducing opioid-induced nausea and vomiting (OINV) in opioid pharmaceuticals, announced preliminary findings from its development and testing of an Opioid Symptoms Questionnaire, or OSQ, which will be used in Charleston's clinical trials.

"This pilot methodology study was designed to test the feasibility and reliability of the OSQ," reported Dr. Bernard Schachtel, Chief Scientific Officer at Charleston Labs. "All patients used the OSQ before and at intervals after ingesting different opioid drugs to indicate the presence and severity of symptoms caused by these medications.

"Using the OSQ prospectively, showing natural progression of opioid side effects," Dr. Schachtel continued, "patients detected different symptoms, not just nausea or vomiting, in good accordance with conventional methods, occasionally with better sensitivity. We will be presenting the final results from this version of the OSQ and other measurement instruments to our Scientific Advisory Board and the clinical investigators for their review and input before completing the protocol for our full-sized clinical trial."

This methodology study was conducted in preparation for Charleston's studies on patients who may experience OINV, the target indication for Charleston's first opioid drug, CL-108. Arrangements are being made with clinical investigators at major universities and research sites in the US to participate in a multi-centered double-blind, randomized, placebo-controlled, multiple-dose safety and efficacy study on over 1,000 patients with post-operative pain. The purpose of this Phase III study is to evaluate CL-108 for relief of acute moderately severe or severe pain and the reduction or elimination of OINV.

All clinical studies for Charleston Laboratories are being overseen by SRC, Inc., a contract research organization based in Jupiter, Florida, which specializes in clinical trials on patients' symptoms (such as nausea).

About Charleston Laboratories, Inc

Charleston Laboratories Inc, headquartered in Charleston, SC, is a privately funded specialty pharmaceutical company developing and commercializing opioid drugs with minimal or no opioid-induced nausea and vomiting (OINV). Charleston Laboratories intends to enter into discovery and commercialization alliances with partners motivated to introduce novel pain therapies that eliminate or significantly reduce nausea and vomiting.

SOURCE Charleston Laboratories, Inc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Doug Flutie, Jr. Foundation Grants NAA $10,000 for Burbacher/Charleston Study
2. The Hope Clinic in Charleston, SC invests in technology to prevent vision loss in patients
3. Charleston, S.C., Market Integration Likely to Drive Physician Groups to Seek Health System Affiliation
4. Charleston Laboratories, Inc. Phase I Clinical Trial
5. Hospital Clínic conducts the first kidney extraction through the vagina in Europe
6. LCA-Vision Conducts 2008 Annual Stockholder Meeting
7. iCRco Conducts First Annual Asia Pacific Distributor Training Program
8. AARP Responds to Senator Grassley, Conducts Comprehensive Review of Marketing of Fixed Benefit Indemnity Products
9. Pennsylvania State Health Department Conducts Pertussis Immunization Clinic in Mercer County
10. NASA Conducts Pilot Cognition Studies
11. New data on hormone therapy must lead to re-evaluation of official guidelines
Post Your Comments:
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... DIEGO , Oct. 12, 2017 AVACEN ... recognized the company with their  2017 New Product Innovation Award ... based on extensive primary and secondary medical device market research ... Medical, through its first-to-market OTC, drug-free pain relief product, the ... unique approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
Breaking Medicine Technology: